AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease

Show full item record



Permalink

http://hdl.handle.net/10138/338130

Citation

Nakken , S , Eikrem , O , Marti , H-P , Beisland , C , Bostad , L , Scherer , A , Flatberg , A , Beisvag , V , Skandalou , E , Furriol , J & Strauss , P 2021 , ' AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease ' , Cancer Cell International , vol. 21 , no. 1 , 690 . https://doi.org/10.1186/s12935-021-02395-9

Title: AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Author: Nakken, Sigrid; Eikrem, Oystein; Marti, Hans-Peter; Beisland, Christian; Bostad, Leif; Scherer, Andreas; Flatberg, Arnar; Beisvag, Vidar; Skandalou, Eleni; Furriol, Jessica; Strauss, Philipp
Contributor organization: Institute for Molecular Medicine Finland
Date: 2021-12-20
Language: eng
Number of pages: 12
Belongs to series: Cancer Cell International
ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02395-9
URI: http://hdl.handle.net/10138/338130
Abstract: Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer and one of the most common cancers. While survival for localized ccRCC is good, the survival of metastatic disease is not, and thirty percent of patients with ccRCC develop metastases during follow-up. Although current scoring methods accurately identify patients at low progression risk, a small subgroup of those patients still experience metastasis. We therefore aimed to identify ccRCC progression biomarkers in "low-risk" patients who were potentially eligible for adjuvant treatments or more intensive follow-up. Methods We assembled a cohort of ccRCC patients (n = 443) and identified all "low-risk" patients who later developed progressing tumors (n = 8). Subsequently, we performed genome-wide expression profiling from formalin-fixed samples obtained at initial surgery from these "low-risk" patients and 16 matched patients not progressing to recurrence with metastasis. The patients were matched for Leibovich sore, creatinine, age, sex, tumor size and tumor stage. Key results were confirmed with qPCR and external data from The Cancer Genome Atlas. Results Principal component analysis indicated that systematic transcriptomic differences were already detectable at the time of initial surgery. One thousand one hundred sixty-seven genes, mainly associated with cancer and immune-related pathways, were differentially expressed between progressors and nonprogressors. A search for a classifier revealed that overexpression of AGAP2-AS1, an antisense long noncoding RNA, correctly classified 23 of 24 samples, years (4.5 years average) in advance of the discovery of metastasis and without requiring larger gene panels. Subsequently, we confirmed AGAP2-AS1 gene overexpression by qPCR in the same samples (p < 0.05). Additionally, in external data from The Cancer Genome Atlas, overexpression of AGAP2-AS1 is correlated with overall unfavorable survival outcome in ccRCC, irrespective of other prognostic predictors (p = 2.44E-7). Conclusion AGAP2-AS1 may represent a novel biomarker identifying high-risk ccRCC patients currently classified as "low risk" at the time of surgery.
Subject: Biomarker
AGAP2-AS1
ccRCC
Low-risk
RNA-seq
PREDICTION
VALIDATION
SIGNATURES
EXPRESSION
LNCRNA
3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
AGAP2_AS1_as_a_prognostic_biomarker_in_...pdf 3.525Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record